As you all know, unless you have been living under a rock for the past year, COVID-19 is something that has most likely impacted everyone on the planet in some way, and in some ways worse than others. At this point in time, I think we can all agree that we just want this madness to end, which is looking like it will come from a vaccine. The vaccine trial process began in March of 2020, where phase 1 was conducted, which was giving the vaccine to healthy volunteers to test the safety and how the vaccine reacts in the human body. This first version of the vaccine was a two dose vaccine, which was designed to get the immune system to create antibodies to fight against what is called the “spike” of the virus, which is how the virus attaches itself and enters human cells. In this specific testing, the researchers used a total of 45 healthy adults ranging from 18 to 55 years of age, each of which receiving two injections of the vaccine, ranging in doses of 25, 100, and 25o micrograms. From this testing, participants received no serious side effects from the vaccine, however, more than half of the participants reported feeling fatigued, chills, and pain at the injection site. This is similar in concept to the taste bud lab we did during class recently, as the miraculin tablets altered our taste buds to have change the taste of certain food items, similar to how the vaccine test altered how the participants felt after taking the test vaccine.
According to the Centers for Disease Control and Prevention (CDC), the goal is for vaccines to be distributed by the end of 2020 in the United States. However, when a vaccine is approved and authorized for distribution, there may not be enough resources for all adults to receive the vaccine when it first comes out. If this is the case, where a vaccine is approved by the end of 2020, and there are not enough resources for all adults at the time, over time, resources will increase leading to all adults being able to have received the vaccine at some point in 2021. As for children, a vaccine may not be available to them as soon as it is available for adults, as more studies are needed to complete a safe vaccine for young children.